MARKET

ALEC

ALEC

Alector
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.57
0.00
0.00%
Pre Market: 14.82 +0.25 +1.72% 09:19 08/06 EDT
OPEN
--
PREV CLOSE
15.02
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
35.93
52 WEEK LOW
13.64
MARKET CAP
1.15B
P/E (TTM)
-8.0117
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALEC stock price target is 35.38 with a high estimate of 44.00 and a low estimate of 28.00.

EPS

ALEC News

More
Alector to Present at the BTIG Virtual Biotechnology Conference 2020
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer, will participate in a fireside chat
GlobeNewswire · 2d ago
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 2d ago
Seeking Alpha Catalyst Watch
Seeking Alpha · 5d ago
Why Alector Is Tumbling 28.7% Today
MotleyFool.com · 07/29 17:00
LB, ADMP, APHA and NMM among midday movers
Seeking Alpha · 07/29 16:42
Sonoma Pharmaceuticals leads healthcare gainers; Aphria and Soligenix among losers
Seeking Alpha · 07/29 15:00
Alector down 25% on hiccup in mid-stage dementia study on lead candidate
Seeking Alpha · 07/29 13:18
STX, BCS among premarket losers
Seeking Alpha · 07/29 12:20

Industry

Biotechnology & Medical Research
+0.18%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About ALEC

Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL101, Al002 and AL003. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).
More

Webull offers kinds of Alector Inc stock information, including NASDAQ:ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.